sur VALBIOTIS (EPA:ALVAL)
Valbiotis expands its range with a solution for menopause
Valbiotis, a French laboratory specializing in food supplements, has announced the launch of ValbiotisPLUS® Menopause & Perimenopause. This new product, available from February 3, 2026, aims to support women during perimenopause and menopause, critical periods for health.
The ValbiotisPLUS® range is therefore expanding to eleven products, offering solutions in pharmacies and online. It is accompanied by the "Menopause and Slowed Metabolism" program, which combines clinically tested products to manage metabolic imbalances during menopause, affecting 14 million women in France.
Valbiotis anticipates revenue growth thanks to this range effect, reinforced by an intensive communication strategy targeting the general public and healthcare professionals.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de VALBIOTIS